Evolocumab Clinical Trials (2026): 125 Studies for Hypercholesterolemia & Hyperlipidemia
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
125 Evolocumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 72 indications (including Hypercholesterolemia & Hyperlipidemia) and 306,014 total planned enrollment. 37 Phase 3 Evolocumab trials and 21 Phase 2, 38 Phase 4 are listed. 12 Evolocumab clinical trials are actively recruiting at 11 U.S. sites across 8 states. Most recent activity: NCT05430828 (Mar 2030).
Where to Participate: All Evolocumab Trial Sites in the U.S. (11 sites across 8 states)
Every actively recruiting Evolocumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| FL | Fortrea Clinical Research Unit - Daytona Beach | Daytona Beach32117-5116 | NCT07422285 | Map |
| MA | Brigham and Women's Hospital | Boston02115 | NCT05152888 | Map |
| MO | QPS Bio-Kinetic | Springfield65802-4842 | NCT07422285 | Map |
| NY | Mount Sinai School of Medicine | New York10029 | NCT05641753 | Map |
| NY | New York VA Hospital | New York10010 | NCT05641753 | Map |
| NY | NYC Health + Hospitals/Bellevue | New York10016 | NCT05641753 | Map |
| NY | NYU Langone Health | New York10016 | NCT05641753 | Map |
| OH | Ohio Clinical Trials, Inc. | Columbus43212 | NCT07422285 | Map |
| PA | UPenn | Philadelphia19104 | NCT06496243 | Map |
| TX | Fortrea Clinical Research Unit - Dallas | Dallas75247 | NCT07422285 | Map |
| WI | Fortrea Clinical Research Unit Inc. - Madison | Madison53704-2526 | NCT07422285 | Map |
Evolocumab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | withdrawn | not yet recruiting | unknown | Total |
|---|---|---|---|---|---|---|---|---|
| Early P1 | 1 | 1 | 1 | 3 | ||||
| P1 | 1 | 3 | 1 | 5 | ||||
| P1/P2 | 1 | 1 | 2 | |||||
| P2 | 2 | 1 | 14 | 1 | 1 | 2 | 21 | |
| P2/P3 | 2 | 2 | ||||||
| P3 | 34 | 2 | 1 | 37 | ||||
| P4 | 2 | 2 | 11 | 4 | 3 | 1 | 15 | 38 |
| N/A | 3 | 5 | 2 | 1 | 6 | 17 |
Recruiting Evolocumab clinical trials (12)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05430828 | AT-TARGET-ITEvaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy | — | Hypercholesterolemia | 5,000 | Mar 2020 |
| NCT06081153 | Mechanistic Clinical Trial of PCSK9 Inhibition for AAA | Early P1 | Abdominal Aortic Aneurysm | 44 | Dec 2026 |
| NCT05152888 | EMPOWERThe Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk | P4 | Stable Coronary Disease | 50 | Mar 2022 |
| NCT06858332 | STaRTLipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia | — | Atherosclerotic Cardiovascular Disease | 2,382 | Apr 2025 |
| NCT05641753 | CHORD1Cholesterol Lowering and Residual Risk in Diabetes, Type 1 | P4 | Type 1 Diabetes | 125 | Dec 2022 |
| NCT07036991 | TRIP-CASClinical Trial of PCSK9 Inhibitor and Statin Treatment for Carotid Artery Stenosis | P4 | Carotid Artery Stenosis | 406 | Jul 2025 |
| NCT06496243 | VINCENTImpact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | P2 | Dyslipidemias | 69 | Dec 2024 |
| NCT07388420 | Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis | N/A | Hypertriglyceridemia Induced Acute Pancreatitis | 40 | Jan 2026 |
| NCT05587621 | GoTIntensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target) | N/A | ST Elevation Myocardial Infarction | 300 | Apr 2024 |
| NCT07545226 | Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose. | P1 | Healthy Participants | 400 | Apr 2026 |
| NCT06700720 | YN001-004 in Patients With Coronary Atherosclerosis in Australia | P2 | Coronary Artery Disease | 24 | Feb 2026 |
| NCT07422285 | Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose | P1 | Healthy Participants | 400 | Jan 2026 |
Evolocumab clinical trials by indication
Hypercholesterolemia (13)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05430828 | AT-TARGET-IT | N/A | recruiting | Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy |
| NCT04790513 | LIBerate-H2H | P3 | completed | Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients |
| NCT04659525 | — | P4 | unknown | Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia |
| NCT04397653 | — | P4 | unknown | Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients |
| NCT01439880 | OSLER | P2 | completed | Open Label Study of Long Term Evaluation Against LDL-C Trial |
| NCT02634580 | GAUSS-4 | P3 | completed | Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4 |
| NCT02304484 | OLE | P3 | completed | Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab |
| NCT03193047 | ETC-1002 | P2 | completed | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy |
| + 5 more, see All trials below. | ||||
Hyperlipidemia (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01984424 | GAUSS-3 | P3 | completed | Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 |
| NCT02275156 | — | P1 | completed | Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab |
| NCT01763918 | RUTHERFORD-2 | P3 | completed | Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 |
| NCT01763866 | LAPLACE-2 | P3 | completed | LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 |
| NCT01763905 | GAUSS-2 | P3 | completed | Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 |
| NCT01763827 | MENDEL-2 | P3 | completed | Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 |
| NCT01375764 | GAUSS | P2 | completed | Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects |
| NCT01380730 | LAPLACE | P2 | completed | LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy |
| + 2 more, see All trials below. | ||||
Atherosclerotic Cardiovascular Disease (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06858332 | STaRT | N/A | recruiting | Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia |
| NCT05974345 | SIRIUS | N/A | completed | In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease |
| NCT04338165 | MICROPROTECT | P2 | unknown | Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography |
| NCT04992065 | — | P2 | completed | A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease |
| NCT03060577 | ORION-3 | P2 | completed | An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol |
| NCT03626831 | EVO | P4 | completed | Effect of Evolocumab on Vascular Function |
| NCT03096288 | — | P4 | completed | Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity |
Coronary Artery Disease (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06700720 | — | P2 | recruiting | YN001-004 in Patients With Coronary Atherosclerosis in Australia |
| NCT04141579 | FITTER | N/A | completed | Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody |
| NCT04710368 | YELLOW III | P4 | completed | Effect of Evolocumab on Coronary Plaque Characteristics |
| NCT03851263 | MARKOV | P4 | withdrawn | Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion |
| NCT05984953 | Yellow V | N/A | completed | Rosuvastatin and Evolocumab for Coronary Artery Disease |
| NCT04073134 | CHORAL | P4 | terminated | The CHORAL Flow Study |
Acute Coronary Syndrome (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03515304 | EVACS | P2 | completed | Evolocumab in Acute Coronary Syndrome |
| NCT04082442 | EVACS II | P2 | completed | Evolocumab in Patients With Acute MI |
| NCT04100434 | EMSIACS | P4 | unknown | Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome |
| NCT05418166 | EvoACS | N/A | unknown | Impact of Evolocumab on the Antiplatelet Effects of Ticagrelor and Aspirin in Patients With Acute Coronary Syndrome |
| NCT04613167 | GEBI | N/A | unknown | Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment |
| NCT03287609 | EVOPACS | P3 | completed | EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) |
Dyslipidemia (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02867813 | FOURIER OLE | P3 | completed | Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension |
| NCT03080935 | — | P3 | terminated | Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries |
| NCT04087915 | FORWARD | N/A | unknown | Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD) |
| NCT02207634 | EBBINGHAUS | P3 | completed | Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects |
| NCT01764633 | FOURIER | P3 | completed | Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk |
Carotid Artery Stenosis (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07036991 | TRIP-CAS | P4 | not yet recruiting | Clinical Trial of PCSK9 Inhibitor and Statin Treatment for Carotid Artery Stenosis |
| NCT03931161 | EVOCAR-1 | P4 | unknown | Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1) |
| NCT04539223 | SLICE-CEA | P4 | unknown | A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy |
Primary Hypercholesterolemia (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03433755 | — | P3 | terminated | Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia |
| NCT01879319 | AMG 145 | P3 | completed | Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen |
| NCT01849497 | AMG 145 | P3 | completed | Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen |
Hypercholesterolemia, Familial (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04313270 | — | N/A | unknown | Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab® |
| NCT06231459 | CytoEx-PCSK9 | P4 | completed | Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 in Familial Hypercholesterolemia |
| NCT01375751 | RUTHERFORD | P2 | completed | Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study |
Healthy Participants (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07545226 | — | P1 | not yet recruiting | Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose. |
| NCT07422285 | — | P1 | recruiting | Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose |
STEMI (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06364124 | — | N/A | unknown | Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction |
| NCT05579418 | — | P4 | unknown | The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients |
Cardiovascular Disease (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05284747 | EVOLVE-MI | P4 | active not recruiting | EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction |
| NCT03689946 | — | P3 | completed | Effect of Evolocumab on Coronary Atherosclerosis |
Homozygous Familial Hypercholesterolemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04034485 | — | P3 | completed | Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH |
| NCT01588496 | TESLA | P2/P3 | completed | Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities |
Familial Hypercholesterolemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02624869 | HAUSER-OLE | P3 | completed | Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia) |
| NCT03331666 | — | P4 | terminated | Impact of LDL-cholesterol Lowering on Platelet Activation |
Peripheral Arterial Disease (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04306081 | Evol-PAD | P4 | unknown | Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease |
| NCT03247972 | — | N/A | terminated | Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease |
Abdominal Aortic Aneurysm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06081153 | — | Early P1 | not yet recruiting | Mechanistic Clinical Trial of PCSK9 Inhibition for AAA |
Hypertriglyceridemia Induced Acute Pancreatitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07388420 | — | N/A | recruiting | Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis |
Dyslipidemias (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06496243 | VINCENT | P2 | recruiting | Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels |
Metastatic Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06284564 | BOOST-RCC | P2 | active not recruiting | A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) |
ST Elevation Myocardial Infarction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05587621 | GoT | N/A | not yet recruiting | Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target) |
Acute Metabolic Effects of Evolocumab and Atorvastatin (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06140095 | — | Early P1 | unknown | Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid Metabolism |
Acute Ischemic Stroke (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06134635 | — | N/A | unknown | Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke |
ASCVD (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05976893 | — | P4 | unknown | Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer |
Stroke Patients With Symptomatic Intracranial Atherosclerotic Stenosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05741086 | EAST-ICAS | P3 | unknown | Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS) |
ST Elevation Myocardial Infarction (STEMI) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05613426 | EVALUATE-STEMI | P4 | terminated | Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI |
Ischemic Stroke, Acute (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05697185 | SEEIS | P4 | unknown | Safety and Efficacy of Evolocumab in Ischemic Stroke |
Type 1 Diabetes (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05641753 | CHORD1 | P4 | recruiting | Cholesterol Lowering and Residual Risk in Diabetes, Type 1 |
Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05661552 | C-STAR | P4 | completed | Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI |
Cerebral Atherosclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05585151 | — | P4 | unknown | High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study |
Adverse Effect of Cardiovascular Medications (Diagnosis) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05802108 | — | P4 | unknown | Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy |
Lung Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05144529 | TOP2101 | P2 | terminated | A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC |
Stable Coronary Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05152888 | EMPOWER | P4 | recruiting | The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk |
Malignant Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04937413 | — | Early P1 | completed | The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation |
STEMI - ST Elevation Myocardial Infarction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04951856 | AMUNDSEN | P4 | active not recruiting | Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI |
Sars-CoV-2 Infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04941105 | IMPACT-SIRIO 5 | P3 | completed | Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19 |
Chronic Kidney Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04510844 | EVO-CKD | P4 | withdrawn | Evolocumab In Advanced Chronic Kidney Disease Trial |
Carotid Artery Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04730973 | CARUSO | P4 | unknown | CARotid plaqUe StabilizatiOn and Regression With Evolocumab. |
Clinical Trial (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04719221 | — | P4 | unknown | Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome |
Hyperlipidemias (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04608474 | — | P4 | completed | Lipid Management in Renal Transplant Recipients Using Evolocumab. |
Multivessel Coronary Artery Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06740552 | EVEREST | N/A | completed | Evolocumab in Patients With Multivessel Coronary Disease After Acute Myocardial Infarction: A Target Trial Emulation |
Critical Limb Ischemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04306471 | Evol-CLI | P4 | unknown | Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI) |
Healthy Subjects (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04189484 | — | P1 | completed | Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors |
ST-elevation Myocardial Infarction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04303377 | ExOTIC | P2 | withdrawn | Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction |
Hereditary Spastic Paraplegia Type 5 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04101643 | — | P1/P2 | unknown | PCSK9 Inhibitor Treatment for Patients With SPG5 |
Familial Dysbetalipoproteinemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03811223 | EVOLVE-FD | P4 | unknown | Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia |
Heart Transplant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03944577 | — | P2 | completed | Impact of Evolocumab in Cardiac Transplant Patients With CAV |
Coronary Heart Disease (CHD) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03872401 | VESALIUS-CV | P3 | completed | Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke |
Cardiac Allograft Vasculopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03734211 | EVOLVD | P3 | completed | Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients |
Atherosclerotic Vascular Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03829046 | — | P4 | completed | The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease |
Coronary Artery Bypass Graft Surgery (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03900026 | NEWTON-CABG | P4 | completed | Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery |
Sepsis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03869073 | PLEASe | P2 | unknown | Evolocumab for PCSK9 Lowering in Early Acute Sepsis (The PLEASe Study) |
Heart Failure With Reduced Ejection Fraction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03791593 | EVO-HF | P2 | completed | EVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF Pilot |
Coronary Artery Disease (CAD) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03570697 | — | P3 | completed | Imaging of Coronary Plaques in Participants Treated With Evolocumab |
Dyslipidemia Associated With Type II Diabetes Mellitus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03932721 | EXCEED-BHS3 | P4 | completed | EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial |
Homozygous Familial Hypercholesterolemia HoFH (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03403374 | RAMAN | P4 | completed | Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia |
Human Immunodeficiency Virus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03500302 | EVOLVE | P2 | completed | Effect of Evolocumab on Coronary Endothelial Function |
Kideny Transplant Recipients With High Cardiovascular Risk Score (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04665830 | — | P3 | completed | PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients |
Diabetes Mellitus, Type 2 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03258281 | ISS-DMII | P4 | terminated | Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus |
Carcinoma, Non-Small-Cell Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03337698 | Morpheus Lung | P1/P2 | terminated | A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) |
Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02833844 | LDL-C | P3 | completed | Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia |
Hypercholesterolemia; ASCVD; Pregnancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02957604 | — | N/A | terminated | Evolocumab Pregnancy Exposure Registry |
Type 2 Diabetes Mellitus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02948777 | — | P4 | completed | Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes |
Lipid Lowering, Vascular Inflammation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02941016 | — | P4 | withdrawn | Vascular Inflammation and Cholesterol Lowering Therapy |
Subjects With Hyperlipidemia, Dyslipidemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02729025 | ANITSCHKOW | P3 | completed | Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)) |
Diabetes, Hyperlipidemia, Mixed Dyslipidemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02662569 | BERSON | P3 | completed | Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia |
Heterozygous Familial Hypercholesterolemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02392559 | HAUSER-RCT | P3 | completed | Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders |
Coronary Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05184530 | — | N/A | completed | In-hospital Initiation of PCSK9 Inhibitor in Patients With Acute Myocardial Infarction |
Primary Hyperlipidemia and Mixed Dyslipidemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02189837 | FLOREY | P3 | completed | Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody |
Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01953328 | AMG145 | P3 | completed | Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk |
Hyperlipidemia and Mixed Dyslipidemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01854918 | OSLER-2 | P3 | completed | Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia |
Hypercholesterolemia and High Risk for Cardiovascular Events (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01652703 | AMG145 | P2 | completed | A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects |
Severe Familial Hypercholesterolemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01624142 | TAUSSIG | P2/P3 | completed | Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders |
Evolocumab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| AMUNDSEN | NCT04951856 | P4 | active not recruiting | STEMI - ST Elevation Myocardial Infarction | 2,166 | — |
| EMPOWER | NCT05152888 | P4 | recruiting | Stable Coronary Disease | 50 | — |
| CHORD1 | NCT05641753 | P4 | recruiting | Type 1 Diabetes | 125 | — |
| EVOLVE-MI | NCT05284747 | P4 | active not recruiting | Cardiovascular Disease | 6,019 | — |
| TRIP-CAS | NCT07036991 | P4 | not yet recruiting | Carotid Artery Stenosis | 406 | — |
| EVALUATE-STEMI | NCT05613426 | P4 | terminated | ST Elevation Myocardial Infarction (STEMI) | 119 | — |
| C-STAR | NCT05661552 | P4 | completed | Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia | 108 | PMID 41560483 |
| NEWTON-CABG | NCT03900026 | P4 | completed | Coronary Artery Bypass Graft Surgery | 782 | PMID 40907505 |
| SEEIS | NCT05697185 | P4 | unknown | Ischemic Stroke, Acute | 200 | PMID 39764289 |
| EVOCAR-1 | NCT03931161 | P4 | unknown | Carotid Artery Stenosis | 33 | — |
| YELLOW III | NCT04710368 | P4 | completed | Coronary Artery Disease | 137 | PMID 31126891 |
| EMSIACS | NCT04100434 | P4 | unknown | Acute Coronary Syndrome | 500 | PMID 41309899 |
| MARKOV | NCT03851263 | P4 | withdrawn | Coronary Artery Disease | 0 | — |
| SLICE-CEA | NCT04539223 | P4 | unknown | Carotid Artery Stenosis | 60 | — |
| CHORAL | NCT04073134 | P4 | terminated | Coronary Artery Disease | 12 | — |
| CARUSO | NCT04730973 | P4 | unknown | Carotid Artery Disease | 130 | PMID 33893754 |
| Evol-CLI | NCT04306471 | P4 | unknown | Critical Limb Ischemia | 32 | — |
| EXCEED-BHS3 | NCT03932721 | P4 | completed | Dyslipidemia Associated With Type II Diabetes Mellitus | 110 | PMID 33062236 |
| EVO-CKD | NCT04510844 | P4 | withdrawn | Chronic Kidney Diseases | 0 | — |
| EVO | NCT03626831 | P4 | completed | Atherosclerotic Cardiovascular Disease | 105 | PMID 40813220 |
| EVOLVE-FD | NCT03811223 | P4 | unknown | Familial Dysbetalipoproteinemia | 30 | — |
| Evol-PAD | NCT04306081 | P4 | unknown | Peripheral Arterial Disease | 86 | — |
| CytoEx-PCSK9 | NCT06231459 | P4 | completed | Hypercholesterolemia, Familial | 20 | PMID 36632236 |
| RAMAN | NCT03403374 | P4 | completed | Homozygous Familial Hypercholesterolemia HoFH | 30 | PMID 34750081 |
| ISS-DMII | NCT03258281 | P4 | terminated | Diabetes Mellitus, Type 2 | 4 | — |
| VESALIUS-CV | NCT03872401 | P3 | completed | Coronary Heart Disease (CHD) | 12,301 | PMID 41903215 |
| EAST-ICAS | NCT05741086 | P3 | unknown | Stroke Patients With Symptomatic Intracranial Atherosclerotic Stenosis | 80 | PMID 40417113 |
| EVOLVD | NCT03734211 | P3 | completed | Cardiac Allograft Vasculopathy | 130 | PMID 40846112 |
| LIBerate-H2H | NCT04790513 | P3 | completed | Hypercholesterolemia | 204 | — |
| IMPACT-SIRIO 5 | NCT04941105 | P3 | completed | Sars-CoV-2 Infection | 60 | PMID 36653090 |
| FOURIER OLE | NCT02867813 | P3 | completed | Dyslipidemia | 5,035 | — |
| HAUSER-OLE | NCT02624869 | P3 | completed | Familial Hypercholesterolemia | 163 | PMID 37855448 |
| LDL-C | NCT02833844 | P3 | completed | Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection | 467 | PMID 32234462 |
| HAUSER-RCT | NCT02392559 | P3 | completed | Heterozygous Familial Hypercholesterolemia | 158 | PMID 32865373 |
| EVOPACS | NCT03287609 | P3 | completed | Acute Coronary Syndrome | 308 | PMID 11277825 |
| OSLER-2 | NCT01854918 | P3 | completed | Hyperlipidemia and Mixed Dyslipidemia | 3,681 | PMID 28844508 |
| GAUSS-4 | NCT02634580 | P3 | completed | Hypercholesterolemia | 61 | PMID 31748467 |
| ANITSCHKOW | NCT02729025 | P3 | completed | Subjects With Hyperlipidemia, Dyslipidemia | 129 | PMID 32393252 |
| OLE | NCT02304484 | P3 | completed | Hypercholesterolemia | 770 | — |
| BERSON | NCT02662569 | P3 | completed | Diabetes, Hyperlipidemia, Mixed Dyslipidemia | 986 | PMID 30851062 |
| GAUSS-3 | NCT01984424 | P3 | completed | Hyperlipidemia | 511 | PMID 27039291 |
| BANTING | NCT02739984 | P3 | completed | Hypercholesterolemia | 424 | PMID 36435949 |
| EBBINGHAUS | NCT02207634 | P3 | completed | Dyslipidemia | 1,974 | PMID 28207168 |
| FOURIER | NCT01764633 | P3 | completed | Dyslipidemia | 27,564 | PMID 40255182 |
| GLAGOV | NCT01813422 | P3 | completed | Hypercholesterolemia | 970 | PMID 33078867 |
| FLOREY | NCT02189837 | P3 | completed | Primary Hyperlipidemia and Mixed Dyslipidemia | 89 | PMID 30897995 |
| AMG145 | NCT01953328 | P3 | completed | Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events | 409 | — |
| RUTHERFORD-2 | NCT01763918 | P3 | completed | Hyperlipidemia | 331 | — |
| LAPLACE-2 | NCT01763866 | P3 | completed | Hyperlipidemia | 2,067 | PMID 29768954 |
| GAUSS-2 | NCT01763905 | P3 | completed | Hyperlipidemia | 307 | PMID 32114889 |
| MENDEL-2 | NCT01763827 | P3 | completed | Hyperlipidemia | 615 | PMID 30755061 |
| DESCARTES | NCT01516879 | P3 | completed | Hypercholesterolemia | 905 | PMID 29221604 |
| AMG 145 | NCT01879319 | P3 | completed | Primary Hypercholesterolemia | 164 | PMID 28717862 |
| AMG 145 | NCT01849497 | P3 | completed | Primary Hypercholesterolemia | 149 | PMID 27066336 |
| VINCENT | NCT06496243 | P2 | recruiting | Dyslipidemias | 69 | — |
| BOOST-RCC | NCT06284564 | P2 | active not recruiting | Metastatic Renal Cell Carcinoma | 10 | — |
| EVACS | NCT03515304 | P2 | completed | Acute Coronary Syndrome | 60 | — |
| EVACS II | NCT04082442 | P2 | completed | Acute Coronary Syndrome | 100 | PMID 37095769 |
| TOP2101 | NCT05144529 | P2 | terminated | Lung Cancer Metastatic | 19 | — |
| MICROPROTECT | NCT04338165 | P2 | unknown | Atherosclerotic Cardiovascular Disease | 66 | PMID 23347861 |
| EVO-HF | NCT03791593 | P2 | completed | Heart Failure With Reduced Ejection Fraction | 46 | — |
| ORION-3 | NCT03060577 | P2 | completed | Atherosclerotic Cardiovascular Disease | 382 | PMID 33990512 |
| PLEASe | NCT03869073 | P2 | unknown | Sepsis | 36 | PMID 25320235 |
| ExOTIC | NCT04303377 | P2 | withdrawn | ST-elevation Myocardial Infarction | 0 | — |
| EVOLVE | NCT03500302 | P2 | completed | Human Immunodeficiency Virus | 19 | PMID 32674634 |
| OSLER | NCT01439880 | P2 | completed | Hypercholesterolemia | 1,324 | PMID 31648705 |
| ETC-1002 | NCT03193047 | P2 | completed | Hypercholesterolemia | 59 | PMID 12672737 |
| AMG145 | NCT01652703 | P2 | completed | Hypercholesterolemia and High Risk for Cardiovascular Events | 310 | PMID 28367845 |
| RUTHERFORD | NCT01375751 | P2 | completed | Hypercholesterolemia, Familial | 168 | PMID 23129602 |
| GAUSS | NCT01375764 | P2 | completed | Hyperlipidemia | 160 | PMID 23128163 |
| LAPLACE | NCT01380730 | P2 | completed | Hyperlipidemia | 631 | PMID 23884353 |
| MENDEL | NCT01375777 | P2 | completed | Hyperlipidemia | 411 | PMID 23141812 |
Terminated and withdrawn Evolocumab trials (14)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05613426terminatedEffect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI
- NCT03337698terminatedA Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
- NCT05144529terminatedA Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
- NCT03851263withdrawnMultislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion
- NCT04073134terminatedThe CHORAL Flow Study
- NCT03080935terminatedFourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries
- NCT04510844withdrawnEvolocumab In Advanced Chronic Kidney Disease Trial
- NCT02941016withdrawnVascular Inflammation and Cholesterol Lowering Therapy
- NCT02957604terminatedEvolocumab Pregnancy Exposure Registry
- NCT04303377withdrawnEarly Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction
- NCT03433755terminatedSafety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia
- NCT03331666terminatedImpact of LDL-cholesterol Lowering on Platelet Activation
- NCT03258281terminatedEffects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus
- NCT03247972terminatedAntiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease
All Evolocumab trials (125)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05430828 | AT-TARGET-IT | Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy | — | recruiting | 5,000 | Federico II University | Mar 2020 |
| NCT06081153 | Mechanistic Clinical Trial of PCSK9 Inhibition for AAA | Early P1 | not yet recruiting | 44 | University of Pennsylvania | Dec 2026 | |
| NCT04951856 | AMUNDSEN | Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI | P4 | active not recruiting | 2,166 | Assistance Publique - Hôpitaux de Paris | Sep 2021 |
| NCT05152888 | EMPOWER | The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk | P4 | recruiting | 50 | Brigham and Women's Hospital | Mar 2022 |
| NCT06858332 | STaRT | Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia | — | recruiting | 2,382 | Novartis Pharmaceuticals | Apr 2025 |
| NCT05641753 | CHORD1 | Cholesterol Lowering and Residual Risk in Diabetes, Type 1 | P4 | recruiting | 125 | NYU Langone Health | Dec 2022 |
| NCT05284747 | EVOLVE-MI | EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction | P4 | active not recruiting | 6,019 | Amgen | Oct 2022 |
| NCT07036991 | TRIP-CAS | Clinical Trial of PCSK9 Inhibitor and Statin Treatment for Carotid Artery Stenosis | P4 | not yet recruiting | 406 | Changhai Hospital | Jul 2025 |
| NCT06496243 | VINCENT | Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | P2 | recruiting | 69 | NewAmsterdam Pharma | Dec 2024 |
| NCT07388420 | Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis | N/A | recruiting | 40 | General Hospital of Shenyang Military Region | Jan 2026 | |
| NCT05587621 | GoT | Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target) | N/A | not yet recruiting | 300 | Jena University Hospital | Apr 2024 |
| NCT06284564 | BOOST-RCC | A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) | P2 | active not recruiting | 10 | M.D. Anderson Cancer Center | Aug 2024 |
| NCT07545226 | Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose. | P1 | not yet recruiting | 400 | Amgen | Apr 2026 | |
| NCT06700720 | YN001-004 in Patients With Coronary Atherosclerosis in Australia | P2 | recruiting | 24 | Beijing Inno Medicine Co., Ltd. | Feb 2026 | |
| NCT07422285 | Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose | P1 | recruiting | 400 | Amgen | Jan 2026 | |
| NCT05613426 | EVALUATE-STEMI | Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI | P4 | terminated | 119 | Henan Institute of Cardiovascular Epidemiology | Apr 2023 |
| NCT06140095 | Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid Metabolism | Early P1 | unknown | 8 | Region Stockholm | Feb 2024 | |
| NCT05976893 | Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer | P4 | unknown | 620 | Xiang Xie | Aug 2023 | |
| NCT04313270 | Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab® | — | unknown | 25 | Federico II University | Dec 2017 | |
| NCT03337698 | Morpheus Lung | A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) | P1/P2 | terminated | 314 | Hoffmann-La Roche | Dec 2017 |
| NCT06740552 | EVEREST | Evolocumab in Patients With Multivessel Coronary Disease After Acute Myocardial Infarction: A Target Trial Emulation | — | completed | 1,862 | Shanghai Zhongshan Hospital | Jan 2021 |
| NCT03872401 | VESALIUS-CV | Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke | P3 | completed | 12,301 | Amgen | Jun 2019 |
| NCT06364124 | Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction | N/A | unknown | 84 | Beijing Luhe Hospital | Jun 2023 | |
| NCT04608474 | Lipid Management in Renal Transplant Recipients Using Evolocumab. | P4 | completed | 81 | Brigham and Women's Hospital | Feb 2021 | |
| NCT03515304 | EVACS | Evolocumab in Acute Coronary Syndrome | P2 | completed | 60 | Johns Hopkins University | May 2018 |
| NCT05661552 | C-STAR | Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI | P4 | completed | 108 | Yonsei University | Dec 2022 |
| NCT03900026 | NEWTON-CABG | Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery | P4 | completed | 782 | Unity Health Toronto | May 2019 |
| NCT04719221 | Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome | P4 | unknown | 60 | Korea University Anam Hospital | Mar 2021 | |
| NCT06134635 | Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke | — | unknown | 80 | Xuanwu Hospital, Beijing | Dec 2023 | |
| NCT05697185 | SEEIS | Safety and Efficacy of Evolocumab in Ischemic Stroke | P4 | unknown | 200 | Second Affiliated Hospital of Guangxi Medical University | Feb 2023 |
| NCT05579418 | The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients | P4 | unknown | 350 | Hamad Medical Corporation | Nov 2022 | |
| NCT04082442 | EVACS II | Evolocumab in Patients With Acute MI | P2 | completed | 100 | Johns Hopkins University | Sep 2019 |
| NCT05585151 | High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study | P4 | unknown | 200 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Nov 2022 | |
| NCT05144529 | TOP2101 | A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC | P2 | terminated | 19 | Eziafa Oduah, MD, PhD, MPH | Mar 2022 |
| NCT05741086 | EAST-ICAS | Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS) | P3 | unknown | 80 | The First Affiliated Hospital with Nanjing Medical University | Apr 2023 |
| NCT05802108 | Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy | P4 | unknown | 60 | Zibo Central Hospital | Jul 2022 | |
| NCT03931161 | EVOCAR-1 | Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1) | P4 | unknown | 33 | Imperial College Healthcare NHS Trust | Sep 2019 |
| NCT05974345 | SIRIUS | In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease | — | completed | 204,691 | Novartis Pharmaceuticals | Nov 2023 |
| NCT04141579 | FITTER | Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody | N/A | completed | 150 | Radboud University Medical Center | Nov 2020 |
| NCT04710368 | YELLOW III | Effect of Evolocumab on Coronary Plaque Characteristics | P4 | completed | 137 | Annapoorna Kini | May 2021 |
| NCT04937413 | The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation | Early P1 | completed | 32 | Duke University | Oct 2021 | |
| NCT04100434 | EMSIACS | Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome | P4 | unknown | 500 | Tianjin Chest Hospital | Jan 2021 |
| NCT03689946 | Effect of Evolocumab on Coronary Atherosclerosis | P3 | completed | 55 | Cedars-Sinai Medical Center | Mar 2019 | |
| NCT03734211 | EVOLVD | Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients | P3 | completed | 130 | Lars Gullestad | Jun 2019 |
| NCT03944577 | Impact of Evolocumab in Cardiac Transplant Patients With CAV | P2 | completed | 26 | University of Nebraska | Jul 2019 | |
| NCT03851263 | MARKOV | Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion | P4 | withdrawn | 0 | ECRI bv | Aug 2019 |
| NCT04034485 | Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH | P3 | completed | 65 | LIB Therapeutics LLC | Dec 2019 | |
| NCT04101643 | PCSK9 Inhibitor Treatment for Patients With SPG5 | P1/P2 | unknown | 30 | First Affiliated Hospital of Fujian Medical University | Sep 2019 | |
| NCT04790513 | LIBerate-H2H | Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients | P3 | completed | 204 | LIB Therapeutics LLC | Apr 2021 |
| NCT04338165 | MICROPROTECT | Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography | P2 | unknown | 66 | University Hospital, Grenoble | Jan 2021 |
| NCT05984953 | Yellow V | Rosuvastatin and Evolocumab for Coronary Artery Disease | — | completed | 195 | Icahn School of Medicine at Mount Sinai | Aug 2013 |
| NCT05418166 | EvoACS | Impact of Evolocumab on the Antiplatelet Effects of Ticagrelor and Aspirin in Patients With Acute Coronary Syndrome | — | unknown | 30 | First Affiliated Hospital of Harbin Medical University | Dec 2021 |
| NCT03791593 | EVO-HF | EVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF Pilot | P2 | completed | 46 | Fundació Institut Germans Trias i Pujol | Dec 2018 |
| NCT04992065 | A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease | P2 | completed | 267 | Novo Nordisk A/S | Aug 2021 | |
| NCT04539223 | SLICE-CEA | A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy | P4 | unknown | 60 | Canadian Medical and Surgical Knowledge Translation Research Group | Aug 2020 |
| NCT04073134 | CHORAL | The CHORAL Flow Study | P4 | terminated | 12 | Imperial College London | Sep 2019 |
| NCT04941105 | IMPACT-SIRIO 5 | Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19 | P3 | completed | 60 | Collegium Medicum w Bydgoszczy | Jun 2021 |
| NCT04730973 | CARUSO | CARotid plaqUe StabilizatiOn and Regression With Evolocumab. | P4 | unknown | 130 | Azienda Ospedaliera Ordine Mauriziano di Torino | Mar 2021 |
| NCT02867813 | FOURIER OLE | Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension | P3 | completed | 5,035 | Amgen | Sep 2016 |
| NCT03080935 | Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries | P3 | terminated | 1,600 | Amgen | Mar 2017 | |
| NCT04306471 | Evol-CLI | Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI) | P4 | unknown | 32 | Leonardo Clavijo | Feb 2020 |
| NCT04087915 | FORWARD | Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD) | — | unknown | 1,000 | Beijing Anzhen Hospital | Sep 2019 |
| NCT05184530 | In-hospital Initiation of PCSK9 Inhibitor in Patients With Acute Myocardial Infarction | — | completed | 7,556 | First Affiliated Hospital Xi'an Jiaotong University | Jan 2016 | |
| NCT04659525 | Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia | P4 | unknown | 50 | Policlinico Casilino ASL RMB | Nov 2020 | |
| NCT03060577 | ORION-3 | An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol | P2 | completed | 382 | Novartis Pharmaceuticals | Apr 2017 |
| NCT03829046 | The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease | P4 | completed | 41 | Robert Rosenson | Jun 2019 | |
| NCT03932721 | EXCEED-BHS3 | EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial | P4 | completed | 110 | University of Campinas, Brazil | Oct 2018 |
| NCT04510844 | EVO-CKD | Evolocumab In Advanced Chronic Kidney Disease Trial | P4 | withdrawn | 0 | NYU Langone Health | Mar 2021 |
| NCT04613167 | GEBI | Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment | N/A | unknown | 70 | University Medical Centre Ljubljana | Nov 2020 |
| NCT03626831 | EVO | Effect of Evolocumab on Vascular Function | P4 | completed | 105 | University of Erlangen-Nürnberg Medical School | Apr 2019 |
| NCT02624869 | HAUSER-OLE | Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia) | P3 | completed | 163 | Amgen | Sep 2016 |
| NCT04189484 | Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors | P1 | completed | 72 | Food and Drug Administration (FDA) | Jan 2020 | |
| NCT03811223 | EVOLVE-FD | Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia | P4 | unknown | 30 | UMC Utrecht | Aug 2019 |
| NCT04306081 | Evol-PAD | Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease | P4 | unknown | 86 | Leonardo Clavijo | Dec 2017 |
| NCT03869073 | PLEASe | Evolocumab for PCSK9 Lowering in Early Acute Sepsis (The PLEASe Study) | P2 | unknown | 36 | University of British Columbia | Feb 2019 |
| NCT03570697 | Imaging of Coronary Plaques in Participants Treated With Evolocumab | P3 | completed | 164 | Amgen | Nov 2018 | |
| NCT06231459 | CytoEx-PCSK9 | Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 in Familial Hypercholesterolemia | P4 | completed | 20 | Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado | Jan 2019 |
| NCT04397653 | Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients | P4 | unknown | 50 | Policlinico Casilino ASL RMB | May 2020 | |
| NCT03096288 | Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity | P4 | completed | 259 | University of Florida | Oct 2017 | |
| NCT02941016 | Vascular Inflammation and Cholesterol Lowering Therapy | P4 | withdrawn | 0 | Rigshospitalet, Denmark | Oct 2016 | |
| NCT02957604 | Evolocumab Pregnancy Exposure Registry | — | terminated | 140 | Amgen | Dec 2016 | |
| NCT04303377 | ExOTIC | Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction | P2 | withdrawn | 0 | Fondazione IRCCS Policlinico San Matteo di Pavia | Nov 2019 |
| NCT03433755 | Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia | P3 | terminated | 259 | Amgen | May 2019 | |
| NCT04665830 | PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients | P3 | completed | 200 | Hamid Al-Essa Organ Transplant Center | May 2018 | |
| NCT03331666 | Impact of LDL-cholesterol Lowering on Platelet Activation | P4 | terminated | 4 | Columbia University | Nov 2018 | |
| NCT02833844 | LDL-C | Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia | P3 | completed | 467 | Amgen | May 2017 |
| NCT03500302 | EVOLVE | Effect of Evolocumab on Coronary Endothelial Function | P2 | completed | 19 | Johns Hopkins University | May 2018 |
| NCT03403374 | RAMAN | Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia | P4 | completed | 30 | Amgen | Aug 2018 |
| NCT02392559 | HAUSER-RCT | Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders | P3 | completed | 158 | Amgen | Mar 2016 |
| NCT03258281 | ISS-DMII | Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus | P4 | terminated | 4 | Inova Health Care Services | May 2018 |
| NCT03247972 | Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease | — | terminated | 30 | Inova Health Care Services | Aug 2017 | |
| NCT03287609 | EVOPACS | EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) | P3 | completed | 308 | Insel Gruppe AG, University Hospital Bern | Jan 2018 |
| NCT02948777 | Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes | P4 | completed | 14 | Marja-Riitta Taskinen | Oct 2016 | |
| NCT01439880 | OSLER | Open Label Study of Long Term Evaluation Against LDL-C Trial | P2 | completed | 1,324 | Amgen | Oct 2011 |
| NCT01854918 | OSLER-2 | Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia | P3 | completed | 3,681 | Amgen | Apr 2013 |
| NCT02634580 | GAUSS-4 | Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4 | P3 | completed | 61 | Amgen | Feb 2016 |
| NCT01624142 | TAUSSIG | Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders | P2/P3 | completed | 300 | Amgen | Jun 2012 |
| NCT02729025 | ANITSCHKOW | Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)) | P3 | completed | 129 | Amgen | Apr 2016 |
| NCT02304484 | OLE | Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab | P3 | completed | 770 | Amgen | Nov 2014 |
| NCT03193047 | ETC-1002 | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy | P2 | completed | 59 | Esperion Therapeutics, Inc. | Apr 2017 |
| NCT03429998 | Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia | P3 | completed | 9 | Hospital General Universitario Gregorio Marañon | Apr 2017 | |
| NCT02662569 | BERSON | Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia | P3 | completed | 986 | Amgen | Apr 2016 |
| NCT01984424 | GAUSS-3 | Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 | P3 | completed | 511 | Amgen | Dec 2013 |
| NCT02739984 | BANTING | Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia | P3 | completed | 424 | Amgen | May 2016 |
| NCT02585895 | Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment | P3 | completed | 39 | Amgen | Dec 2015 | |
| NCT02207634 | EBBINGHAUS | Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects | P3 | completed | 1,974 | Amgen | Sep 2014 |
| NCT01764633 | FOURIER | Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk | P3 | completed | 27,564 | Amgen | Feb 2013 |
| NCT01813422 | GLAGOV | GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound | P3 | completed | 970 | Amgen | Apr 2013 |
| NCT02189837 | FLOREY | Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody | P3 | completed | 89 | Amgen | Jul 2014 |
| NCT02275156 | Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab | P1 | completed | 18 | Amgen | Aug 2014 | |
| NCT01953328 | AMG145 | Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk | P3 | completed | 409 | Amgen | Oct 2013 |
| NCT01588496 | TESLA | Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities | P2/P3 | completed | 58 | Amgen | Apr 2012 |
| NCT01763918 | RUTHERFORD-2 | Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 | P3 | completed | 331 | Amgen | Feb 2013 |
| NCT01763866 | LAPLACE-2 | LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 | P3 | completed | 2,067 | Amgen | Jan 2013 |
| NCT01763905 | GAUSS-2 | Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 | P3 | completed | 307 | Amgen | Jan 2013 |
| NCT01763827 | MENDEL-2 | Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 | P3 | completed | 615 | Amgen | Jan 2013 |
| NCT01516879 | DESCARTES | Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study | P3 | completed | 905 | Amgen | Jan 2012 |
| NCT01879319 | AMG 145 | Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen | P3 | completed | 164 | Amgen | Jul 2013 |
| NCT01849497 | AMG 145 | Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen | P3 | completed | 149 | Amgen | Apr 2013 |
| NCT01652703 | AMG145 | A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects | P2 | completed | 310 | Amgen | Jul 2012 |
| NCT01375751 | RUTHERFORD | Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study | P2 | completed | 168 | Amgen | Aug 2011 |
| NCT01375764 | GAUSS | Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects | P2 | completed | 160 | Amgen | Jul 2011 |
| NCT01380730 | LAPLACE | LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy | P2 | completed | 631 | Amgen | Jul 2011 |
| NCT01375777 | MENDEL | Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels | P2 | completed | 411 | Amgen | Jul 2011 |
| NCT01133522 | AMG 145 | Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin | P1 | completed | 60 | Amgen | Jun 2010 |
Evolocumab clinical trials: frequently asked questions
- How many Evolocumab clinical trials are there?
- 125 Evolocumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 8 are actively recruiting participants. 70 are marked completed.
- Are Evolocumab clinical trials recruiting in 2026?
- Yes — 8 Evolocumab trials are actively recruiting in 2026, with 11 U.S. sites across 8 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Evolocumab being studied for?
- Evolocumab is being studied for Hypercholesterolemia, Hyperlipidemia, Atherosclerotic Cardiovascular Disease, Acute Coronary Syndrome, Coronary Artery Disease and 101 more. The trials are grouped by indication on this page.
- What phase is Evolocumab in?
- Evolocumab clinical trials span 38 Phase 4, 37 Phase 3, 21 Phase 2, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Evolocumab clinical trials?
- The lead sponsor across the most Evolocumab trials is Amgen, with 71 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Evolocumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: